# Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)

> **NCT02525263** · PHASE2 · TERMINATED · sponsor: **Prokidney** · enrollment: 1 (actual)

## Conditions studied

- Chronic Kidney Disease
- Type 2 Diabetes

## Interventions

- **BIOLOGICAL:** Neo-Kidney Augment

## Key facts

- **NCT ID:** NCT02525263
- **Lead sponsor:** Prokidney
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-07
- **Primary completion:** 2017-05
- **Final completion:** 2017-08
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** The single patient enrolled began hemodialysis treatments.
- **Last updated:** 2021-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02525263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02525263, "Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02525263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*